HAMI3379 is a potent and selective cysteinyl leukotriene receptor 2 (CysLT2) antagonist; it exhibits neuroprotective effects against acute and subacute ischemic brain injury; attenuates microglia-associated inflammation; reduces neurological deficits, infarct volume, brain edema, and neuronal loss and degeneration following middle cerebral artery occlusion (MCAO); and inhibits and reverses LTC4-induced increases in perfusion pressure and decreases in contractility in a concentration-dependent manner.